SAN CLEMENTE, Calif. & SHANGHAI--(BUSINESS WIRE)--ReFlow Medical, Inc. (ReFlow) today announced that it has signed an exclusive distribution and sales agreement for ReFlow's suite of peripheral chronic total occlusion (CTO) products with MicroPort Endovascular (MicroPort Endo), a division of MicroPort Scientific Corporation (MicroPort), a leading medical device company in China.
ReFlow has developed a suite of products to cost-effectively address unmet needs in the CTO market. ReFlow’s Wingman crossing catheter is 510(k) cleared and CE Marked to be used in conjunction with steerable guidewires to access discrete regions of the peripheral vasculature and enable rapid, routine, off-the-shelf lesion crossing. The Wingman is the first of several new product families to address the clinical challenges of the CTO market that ReFlow plans to introduce around the world.
"MicroPort’s successful history of obtaining timely regulatory approvals, launching new products, and rapidly expanding market share makes it an ideal partner for us in China," Isa Rizk, President and CEO of ReFlow, said. "We look forward to working with MicroPort to develop this important market and to drive market adoption of ReFlow's products."
Zhonghua Li, Executive Vice General Manager of MicroPort Endo, commented that, "We are very pleased to have entered into this long-term distribution agreement with ReFlow. ReFlow’s products provide a unique solution to addressing the growing CTO opportunity in China with a cost-effective, and easy-to-use solution."
About ReFlow Medical, Inc.
ReFlow Medical, Inc. is a private company focused on the design and development of simple and effective technologies that empower the physician when accessing and treating discrete regions of the peripheral and coronary vasculature.
For more information, please refer to: www.reflowmedical.com
MicroPort Scientific Corporation (the "Group") is a leading medical device company listed on the main board of Hong Kong (HK: 853), with business focusing on innovating, manufacturing, and marketing high-quality and high-end medical devices globally. The Group maintains world-wide operations in a broad range of business segments including Cardiovascular, Orthopedic, Electrophysiological, Endovascular, Neurovascular, Surgical, Diabetes Care and Endocrinal Management, and others. MicroPort is dedicated to becoming a leading global enterprise capable of providing the best and yet most affordable medical products and technologies to serve patients throughout the world.
For more information, please refer to: www.microport.com